RAPT Therapeutics (RAPT ) stock price, revenue, and financials

RAPT Therapeutics market cap is $671.5 m, and annual revenue was $5.04 m in FY 2020

$671.5 M

RAPT Mkt cap, 13-Jul-2020

$1.2 M

RAPT Therapeutics Revenue Q1, 2021
RAPT Therapeutics Net income (Q1, 2021)-16.5 M
RAPT Therapeutics EBIT (Q1, 2021)-16.6 M
RAPT Therapeutics Cash, 31-Mar-202124.7 M
Get notified regarding key financial metrics and revenue changes at RAPT TherapeuticsLearn more
Banner background

RAPT Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2020

Revenue

5.0m

R&D expense

25.6m31.8m45.5m

General and administrative expense

3.7m5.2m12.8m

Operating expense total

29.3m36.9m58.3m

EBIT

(29.3m)(36.9m)(53.2m)

EBIT margin, %

(1055%)

Pre tax profit

(51.9m)

Income tax expense

990.0k

Net Income

(29.1m)(36.1m)(52.9m)

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

935.0k1.3m1.2m

R&D expense

8.6m10.7m11.0m13.8m

General and administrative expense

1.7m3.3m2.8m4.0m

Operating expense total

10.3m14.0m13.8m17.8m

EBIT

(13.0m)(12.5m)(16.6m)

EBIT margin, %

(1394%)(980%)(1355%)

Interest expense

344.0k

Pre tax profit

(12.9m)(12.1m)(16.5m)

Income tax expense

237.0k267.0k

Net Income

(10.0m)(13.1m)(12.4m)(16.5m)

RAPT Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

47.5m63.8m77.4m24.9m

Prepaid Expenses

725.0k1.3m3.1m4.1m

Current Assets

48.2m65.1m80.5m115.6m

PP&E

1.9m4.2m3.7m3.0m

Total Assets

50.4m69.6m84.6m119.0m

Accounts Payable

1.1m1.8m1.1m2.4m

Current Liabilities

3.2m4.6m9.3m11.7m

Non-Current Liabilities

905.0k969.0k

Total Liabilities

14.8m

Common Stock

1.0k1.0k2.0k2.0k

Preferred Stock

108.6m161.1m

Additional Paid-in Capital

21.0m22.4m235.0m319.2m

Retained Earnings

(82.8m)(119.0m)(161.9m)(214.8m)

Total Equity

46.2m64.0m73.1m104.2m

Financial Leverage

1.1 x1.1 x1.2 x1.1 x

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

48.3m91.5m29.0m24.7m

Accounts Receivable

5.0m

Prepaid Expenses

2.9m3.7m3.1m4.2m

Current Assets

51.2m146.9m136.1m102.6m

PP&E

4.0m3.6m3.2m2.9m

Total Assets

58.4m150.9m139.7m105.9m

Accounts Payable

1.6m3.4m2.4m3.1m

Current Liabilities

5.5m13.4m13.1m11.1m

Total Liabilities

14.3m

Common Stock

1.0k2.0k2.0k2.0k

Additional Paid-in Capital

23.9m307.0m309.9m323.2m

Retained Earnings

(148.7m)(175.1m)(187.5m)(231.4m)

Total Equity

(124.8m)131.9m122.6m91.6m

Financial Leverage

-0.5 x1.1 x1.1 x1.2 x

RAPT Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(29.1m)(36.1m)(43.0m)(52.9m)

Depreciation and Amortization

1.4m1.2m1.3m1.1m

Accounts Payable

(80.0k)1.5m736.0k2.4m

Cash From Operating Activities

(27.1m)(33.0m)(35.5m)(40.5m)

Purchases of PP&E

(1.1m)(3.5m)(888.0k)(398.0k)

Cash From Investing Activities

(1.1m)(3.5m)(843.0k)(87.4m)

Dividends Paid

Cash From Financing Activities

30.1m52.7m49.9m75.5m

Net Change in Cash

1.9m16.3m13.6m(52.5m)

Income Taxes Paid

660.0k990.0k

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(29.8m)(13.1m)(25.5m)(16.5m)

Depreciation and Amortization

1.0m199.0k595.0k280.0k

Accounts Receivable

(5.0m)

Accounts Payable

2.2m2.4m1.8m362.0k

Cash From Operating Activities

(29.8m)(8.7m)(15.2m)(13.9m)

Purchases of PP&E

(863.0k)(98.0k)(98.0k)(227.0k)

Cash From Investing Activities

(863.0k)(47.0m)(104.0m)12.4m

Dividends Paid

Cash From Financing Activities

15.2m69.9m70.7m1.3m

Net Change in Cash

(15.5m)14.1m(48.4m)(198.0k)

RAPT Therapeutics Ratios

USDFY, 2017

Financial Leverage

1.1 x

RAPT Therapeutics Employee Rating

4.79 votes
Culture & Values
4.8
Work/Life Balance
3.9
Senior Management
4.4
Salary & Benefits
4.6
Career Opportunities
4.4
Source